Genflow's dog gene trial: £500K raised for SIRT6 therapy

Proactive - Interviews for investors

Genflow Biosciences PLC (LSE:GENF, OTCQB:GENFF) CEO Dr Eric Leire talked with Proactive's Stephen Gunnion about the company’s latest milestone—a successful £0.5 million fundraising to support a gene therapy trial in ageing dogs using SIRT6. Dr Leire explained that the funding was secured via a share subscription from a US-based longevity fund, with shares issued at market price and without a discount—what he described as a clear “vote of confidence in the company and its therapies.” Dr Leire explained that the funding was secured via a share subscription from a US-based longevity fund, with shares issued at market price and without a discount—what he described as a clear “vote of confidence in the company and its therapies.” The trial aims to demonstrate proof of concept in dogs, replicating promising results previously seen in mice. “It worked like magic in mice. We reasonably think that it will work likewise in dogs,” Leire stated. Unlike mice, however, dogs share environmental conditions with humans, making them a more relevant model for translation into human therapies. Leire also highlighted the commercial potential of targeting animal health, as it offers a shorter regulatory pathway compared to human applications. He confirmed that the trial has reached a key milestone: the randomisation of 24 senior dogs, aged over ten years, into four arms, including one control group and three treatment groups using different SIRT6 delivery methods. He also addressed ethical considerations, stating that the therapy does not involve genetic modification, and described the use of non-integrating gene therapy approaches, including naked DNA and AAV vectors. Visit Proactive's YouTube channel for more videos, and don't forget to give the video a like, subscribe to the channel and enable notifications for future content. #GenflowBiosciences #GeneTherapy #SIRT6 #DogAgingTrial #LongevityResearch #BiotechFunding #AnimalHealth #AntiAging #Biotechnology #ClinicalTrials #LifeSciences #InvestingInBiotech #SeniorDogs